R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.

R&D

While support for reducing animal use has never been stronger, the path to broad adoption is steep and complex.

R&D

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.

R&D

Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.

R&D

An emerging consensus across sponsors, investigators, and regulators is that agility must become a defining attribute of CRO performance.

R&D

Data shows countries are off track – increasing the risk of profound health and economic consequences from AMR. Medical technologies can help.